A 52-year-old woman presented to the emergency department with 2 episodes of thunderclap headaches separated by about 8 hours, both occurring during defecation. She had a history of chronic nasal congestion, asthma, chronic back pain, and low mood without other major depressive features or suicidality. She had no history of hypertension. Her medications consisted of a budesonide–formoterol inhaler, salbutamol taken as needed, duloxetine 60 mg/d (a serotonin-norepinephrine reuptake inhibitor [SNRI]) and xylometazoline topical nasal decongestant spray taken once daily. The patient described periodic worsening of nasal congestion, which led her to increase her xylometazoline dosage. At the time of presentation, she was using the nasal decongestant 2–3 times daily and she had been taking duloxetine daily for 1.5 years. She did not have a history of tobacco smoking, problem drinking or recreational substance use.

On examination, she was hypertensive at 215/108 mm Hg, but after receiving analgesia, antiemetics and fluids, her blood pressure improved to 155/90 mm Hg. She had a Glasgow Coma Scale score of 15, a supple neck, and no associated focal neurologic deficits, seizure activity or encephalopathy. She had severe inferior nasal turbinate hypertrophy; hyperemic nasal mucosa; minimal thin, clear secretions; and moderate right nasal septal deviation without septal perforation.

Initial computed tomography (CT) of the head and CT angiography showed small areas of convexal subarachnoid hemorrhage as well as multifocal mild-to-moderate narrowing in the intracranial arteries of the anterior and posterior circulation with a string-of-beads appearance (Figure 1). The patient’s presentation was compatible with reversible cerebral vasoconstriction syndrome given the history of recurrent thunderclap headaches, triggered by a Valsalva effect from straining, exposure to 2 vasoconstrictive medications, and classic imaging findings of widespread symmetric cerebral artery narrowing and small atraumatic convexal subarachnoid hemorrhage. The term “convexal” denotes a hemorrhage distribution limited to convexities of the brain without involving adjacent brain parenchyma or extending into interhemispheric fissures, basal cisterns or ventricles. Computed tomography and CT angiography were adequate noninvasive investigations in this case, because of the convexal pattern of the subarachnoid hemorrhage. We did not do a lumbar puncture, which is reserved for investigating thunderclap headache in the setting of a normal CT to exclude a small subarachnoid hemorrhage without an aneurysm seen on CT angiography.1

We tapered the duloxetine 60 mg/d down to 30 mg every other day for 3 doses and stopped, after confirming that her primary indication was for sciatica, which was well controlled. We also weaned and discontinued the xylometazoline, and given the patient’s severe nasal congestion and comorbid asthma, we prescribed montelukast 10 mg/d along with beclomethasone nasal spray 50 µg, 2 sprays each nostril daily, as an effective and safer long-term option for her nasal congestion related to suspected allergic rhinitis. We discussed the rationale for using intranasal steroids rather than decongestant sprays. Finally, to

**KEY POINTS**

- Thunderclap headaches warrant emergent evaluation for aneurysmal subarachnoid hemorrhage and reversible cerebral vasoconstriction syndrome, which are the 2 most common causes.
- The most common cause of atraumatic convexal subarachnoid hemorrhage in patients aged 60 years or younger is reversible cerebral vasoconstriction syndrome.
- Exposure to vasoactive substances (e.g., adrenergic agonists and serotonergic medications) is a known risk factor for reversible cerebral vasoconstriction syndrome; multiple concomitant exposures may interact additively to further increase the risk of reversible cerebral vasoconstriction syndrome.
- All patients taking nasal decongestants should be counselled about the risk of rhinitis medicamentosa if nasal decongestants are used regularly for more than 3–5 days and the risk of reversible cerebral vasoconstriction syndrome, especially if there are concomitant exposures to vasoactive substances.
hasten reversal of the cerebral vasoconstriction, we admitted the patient and started treatment with verapamil immediate release, a calcium channel blocker, 120 mg orally every 8 hours. After 2 weeks of therapy, we ordered repeat imaging to verify angiographic stability before discharge. It showed resolved subarachnoid hemorrhage and mild interval improvement in the intracranial arterial stenoses in the bilateral anterior, middle and posterior cerebral arteries. We discharged the patient taking verapamil extended release 180 mg twice daily with follow-up in the stroke prevention clinic, and we advised her to avoid nasal decongestants, serotonergic antidepressants and other vasoactive drugs such as dihydroergotamine and triptans, if possible. She has had no further episodes of headache as of last follow-up.

Figure 1: Computed tomography angiogram of the head in a 52-year-old woman who presented to the emergency department with 2 episodes of thundrerclap headaches, showing multifocal segmental mild-to-moderate stenoses bilaterally in the circle of Willis and its branches in both anterior and posterior circulation. Colloquially, this creates a “string-of-beads” appearance (arrows). (A) Axial, (B,C) sagittal and (D) coronal views.
After her hospital stay, our patient also saw an allergist, who used specific immunoglobulin E testing to identify an allergy to cats. Thus, her year-round congestion could be attributed to her pet cat. Although we recommended that she completely avoid contact with her cat, she was not ready and opted for subcutaneous immunotherapy. She was further assessed by an otorhinolaryngologist to identify nonallergic factors contributing to severe chronic nasal congestion, with consideration of nasal septal correction and turbinate reduction.

Discussion

Reversible cerebral vasoconstriction syndrome versus aneurysmal subarachnoid hemorrhage
The term thunderclap headache describes a headache that reaches maximal intensity at onset. The 2 most common and urgent causes of thunderclap headache to consider are reversible cerebral vasoconstriction syndrome and aneurysmal subarachnoid hemorrhage (Box 1). A prospective study involving 173 patients with reversible cerebral vasoconstriction syndrome found that 71% were female, 32% had a history of migraines, 49%–60% were exposed to vasoactive substances and 8%–12% were postpartum.2 The authors found that thunderclap headache was present in 94% and tended to be recurrent (87%) and provoked (77%), and associated with sexual intercourse (27%), exertion (22%) or acute emotional stress (19%).2 Other reported associations include defecation, urination, cough, sneezing, bathing or showering.3 Differentiating reversible cerebral vasoconstriction syndrome from aneurysmal subarachnoid hemorrhage is essential, and we consulted the on-call neurosurgeon, who concluded that, based on the patient’s convexal subarachnoid hemorrhage pattern and multifocal multivessel narrowing, reversible cerebral vasoconstriction syndrome was the most likely diagnosis, not subarachnoid hemorrhage related to a ruptured aneurysm. In patients aged 60 years or younger, the most common cause of atraumatic convexal subarachnoid hemorrhage is reversible cerebral vasocostriction syndrome.4

Risk factors for reversible cerebral vasocostriction syndrome
Reversible cerebral vasocostriction syndrome has a long list of putative risk factors without a fully unifying mechanism; however, drugs and conditions associated with vasocostriction have been most consistently observed. Two prospective cohort studies identified the postpartum state and exposure to at least 1 vasoactive substance as risk factors.2,3 The top 3 vasoactive substances were cannabis (20%–32%), selective serotonin reuptake inhibitors (SSRIs) (13%–21%) and nasal decongestants (13%).2,3 Other less common vasoactive substances included alcohol (binge drinking), cocaine, corticosteroids, interferon-α, nicotine patches, ergots, triptans, SNRIs, epinephrine, cyclosporine and sulprostone.2,3 Exposure to a single vasoactive substance was observed in 39%, and multiple exposures were documented in 14.5% of cases.3 The most common multiple exposures involved cannabis with alcohol binge drinking (6%) or cannabis with a nasal decongestant (3%); an SSRI combined with

### Box 1: Comparison of aneurysmal subarachnoid hemorrhage and reversible cerebral vasocostriction syndrome

| Characteristic                  | Aneurysmal SAH | RCVS |
|--------------------------------|---------------|------|
| **Epidemiology**               |               |      |
| Incidence                      | 3–25/100 000  | Unknown |
| Age, yr                        | 40–60         | 10–76 |
|                               | Peak 50       | Mean 40–45 |
| Sex, female-to-male ratio      | Female > male after fifth decade (1.6) | Female > male, 2 to 10:1 |
| **Clinical features**          |               |      |
| Risk factors                   | Hypertension  | > 60% of cases with identifiable risk factor |
|                               | Cigarette smoking |                  |
|                               | Family history/genetic |                  |
|                               | Alcohol       |                  |
|                               | Sympathomimetic drugs |                  |
| Headache features              | Single thunderclap headache | Recurrent thunderclap headache (mean of 4) |
|                               | Sentinel headache (10%–43%) | Short duration 1–3 h |
|                               | Longer duration |                  |
| **Physical examination**       | Altered level of consciousness | More often normal |
|                               | Focal neurologic deficit | Focal neurologic deficit (if associated with stroke) |
|                               | Seizure       | Seizure |
| **Imaging and other tests**    |               |      |
| Brain imaging                  | Perisylvian SAH | Atraumatic convexal SAH |
|                               | Perimesencephalic subarachnoid intraparenchymal hemorrhage, subdural hemorrhage, intraventricular hemorrhage | Normal (30%–70%) |
| Lumbar puncture                | Elevated erythrocytes (from tube 1 to 4) | Normal or mild elevated white cells and or protein |
|                               | Positive xanthochromia |                  |
|                               | Elevated opening pressure |                  |
| **Vascular imaging**           | Aneurysm      | Multifocal segmental cerebral vasocostriction (string and beads) |
|                               |               | Reversible within 3 mo |
| **Lumbar puncture**            | Elevated erythrocytes (from tube 1 to 4) | Normal or mild elevated white cells and or protein |
|                               | Positive xanthochromia |                  |
|                               | Elevated opening pressure |                  |
| **Prognosis**                  | Mortality rate 8%–67% (median mortality rate 32% in the US) | < 5% with life-threatening form of RCVS |
|                               | Rate of persistent dependence 8%–20% | < 15%–20% mild deficit |
| **Recurrence**                 | 2.2% at 10 yr | Recurrence in 5%–6% at 3.4 yr |

Note: CT = computed tomography, MRI = magnetic resonance imaging, RCVS = reversible cerebral vasocostriction syndrome, SAH = subarachnoid hemorrhage.
a nasal decongestant was observed in 1% of cases. Our patient’s new-onset recurrent thunderclap headaches associated with increased use of xylometazoline and chronic use of duloxetine was highly suspicious for reversible cerebral vasospasm. Similar to our case, Loewen and colleagues described a 31-year-old woman with thunderclap headache associated with chronic use of oxymetazoline, another topical nasal decongestant, and sertraline, an SSRI. The patient had clinical and radiologic resolution after stopping oxymetazoline and receiving treatment with nimodipine, a calcium channel blocker.

Management of reversible cerebral vasospasm syndrome

No randomized controlled trials have been conducted to guide the management of reversible cerebral vasospasm syndrome. The mainstay of treatment is early recognition, rest and removal of offending agents, as reversible cerebral vasospasm syndrome is often self-limited with no new symptoms after 4 weeks and angiographic resolution by 3 months. Symptomatic treatment of headache is recommended with simple analgesics, and sertraline, another topical nasal decongestant, spray, and sertraline, an SSRI. The patient had clinical and radiologic resolution after stopping oxymetazoline and receiving treatment with nimodipine, a calcium channel blocker.

Rhinitis medicamentosa as a risk factor for reversible cerebral vasospasm syndrome

Along with reversible cerebral vasospasm syndrome, this patient was also diagnosed with rhinitis medicamentosa based on severe chronic nasal congestion and chronic xylometazoline use. Rhinitis medicamentosa is a special type of medication-induced rhinitis due to prolonged use of a topical α-adrenergic receptor agonist (e.g., oxymetazoline, xylometazoline and phenylephrine) for more than 3-5 days. It can manifest as rebound nasal congestion, tachyphylaxis and impaired mucociliary clearance, predisposing the patient to a vicious cycle of refractory nasal congestion caused by and transiently relieved by the intranasal decongestant. By conducting a full clinical evaluation of chronic nasal obstructive symptoms, we can explore possible allergic triggers to avoid, offer patients targeted and highly effective treatments, and discuss the negative impacts of readily accessible over-the-counter nasal decongestants. Nasal decongestants when combined with other common vasoactive substances, such as serotonergic antidepressants, cannabis and alcohol (binge drinking), may increase the risk of reversible cerebral vasospasm syndrome. Health care professionals should be aware of these potential interactions and advise their patients accordingly.

References

1. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet 2017;389:655-66.
2. de Boysson H, Parienti JJ, Mawet J, et al. Primary angiitis of the CNS and reversible cerebral vasospasm syndrome: a comparative study. Neurology 2018;91:e1468-78.
3. Ducros A, Boukobza M, Porcher R, et al. The clinical and radiological spectrum of reversible cerebral vasospasm syndrome. A prospective series of 67 patients. Brain 2007;130:391-101.
4. Kumar S, Goddeau RP Jr, Selim MH, et al. Atraumatic convexal subarachnoid hemorrhage: clinical presentation, imaging patterns, and etiologies. Neurology 2010;74:893-9.
5. Loewen AHS, Hudson ME, Hill MD. Thunderclap headache and reversible segmental cerebral vasospasm associated with use of oxymetazoline nasal spray. CMAJ 2004;171:593-4.
6. Cappelen-Smith C, Calic Z, Cordato D. Reversible cerebral vasospasm syndrome: recognition and treatment. Curr Treat Options Neurol 2017;19:21.
7. Rocha EA, Topcuoglu MA, Silva GS, et al. RVCS2 score and diagnostic approach for reversible cerebral vasospasm syndrome. Neurology 2019;92:e639-47.
8. Lawton MT, Yates GE. Subarachnoid hemorrhage. N Engl J Med 2017;377:257-66.
9. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al.; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43:1711-37.
10. Boulanger JM, Lindsay MP, Gubitz G, et al. Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, update 2018. Int J Stroke 2018;13:949-84.